Search

Displaying results 7151 - 7160 of 10000 in total
  1. Drug

    Tomivosertib

    go.drugbank.com/drugs/DB15219
    Investigational

    Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).

  2. Drug

    VS-4718

    go.drugbank.com/drugs/DB15273
    Investigational

    VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).

  3. Drug

    Tefinostat

    go.drugbank.com/drugs/DB15321
    Investigational

    Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).

  4. Drug

    Lacutamab

    go.drugbank.com/drugs/DB15322
    Investigational

    Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

  5. Drug

    Axomadol

    go.drugbank.com/drugs/DB16100
    Investigational

    Axomadol is under investigation in clinical trial NCT01043263 (Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain).

    Synonyms: Bn-110 free base
  6. Drug

    Empegfilgrastim

    go.drugbank.com/drugs/DB16155
    Investigational

    Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer).

  7. Drug

    CHIR-124

    go.drugbank.com/drugs/DB06852
    Experimental

    CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

  8. Drug

    Tretazicar

    go.drugbank.com/drugs/DB04253
    Investigational

    Tretazicar is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).

  9. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

  10. Drug

    COVID-19 convalescent plasma

    go.drugbank.com/drugs/DB15692
    Investigational

    ), and use for single patients through an emergency IND (eIND; 21 CFR 312.310). … [L14333] This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305